After a decade of legal challenges, Prevagen, a popular brain supplement derived from jellyfish, has been compelled by courts to acknowledge its product does not improve memory. The settlement marks the culmination of a lengthy legal battle initiated over concerns about misleading advertising and unsubstantiated claims.

The Federal Trade Commission (FTC) and multiple state attorneys general brought suit against Prevagen, alleging that the company falsely advertised the supplement’s ability to enhance cognitive function and memory. Consumers had filed numerous complaints questioning the product's efficacy, prompting further scrutiny and ultimately, the lawsuit.

Prevagen's active ingredient, apoaequorin, is sourced from jellyfish. While initial research suggested potential neuroprotective properties, subsequent studies failed to demonstrate a significant impact on memory or cognitive performance in humans. The company has now agreed to cease deceptive marketing practices and provide refunds to customers who purchased Prevagen based on the disputed claims.

The settlement requires Prevagen to clearly state that its product hasn't been proven to improve memory. Experts emphasize the importance of relying on evidence-based strategies for maintaining brain health, such as regular exercise, a balanced diet, sufficient sleep, and cognitive stimulation through activities like reading and puzzles. This case serves as a cautionary tale for consumers and highlights the need for rigorous scientific validation of health supplements before marketing them with claims of cognitive enhancement.

Details of the refund process and specific terms of the settlement are available on the FTC’s website. Consumers who believe they were misled by Prevagen’s advertising are encouraged to explore their options for seeking reimbursement.